Cargando…

Follicular Lymphomas of Oral Region Treated by Rituximab Monotherapy: About Two Cases

Lymphomas represent the second most common malignant lesions of the head and neck. Among them, follicular lymphomas (FLs) are the second most frequent B-cell non-Hodgkin’s lymphomas. However, their incidence is rare in the oral cavity. We describe here two cases of FL with initial intra-oral present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montaner, Sylvain, Weingertner, Noelle, Ledoux, Marie-Pierre, Chenard, Marie-Pierre, Lutz, Jean-Christophe, Bornert, Fabien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155859/ https://www.ncbi.nlm.nih.gov/pubmed/32300407 http://dx.doi.org/10.14740/jh346w

Ejemplares similares

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
por: Enqvist, Monika, et al.
Publicado: (2019)

Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings()()
por: Fattori, Antonin, et al.
Publicado: (2021)

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide
por: Chenard, Marie-Pierre, et al.
Publicado: (2015)

Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report
por: Klienkoff, Pierre, et al.
Publicado: (2023)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma
por: Alvarez-Sánchez, A.I., et al.
Publicado: (2018)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites
por: Hiroshima, Yuki, et al.
Publicado: (2012)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab
por: Tariq, Anam, et al.
Publicado: (2017)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Reversible rituximab-induced rectal Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
por: Billon, Emilien, et al.
Publicado: (2018)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Idiopathic Orbital Inflammation Treated With Rituximab Monotherapy
por: Bawazeer, Amani, et al.
Publicado: (2023)

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab
por: Rodier, Cyrielle, et al.
Publicado: (2023)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C
por: Erbe, A K, et al.
Publicado: (2013)

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study
por: Herfarth, Klaus, et al.
Publicado: (2018)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report
por: Aagre, Suhas, et al.
Publicado: (2015)

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
por: Nastoupil, Loretta J, et al.
Publicado: (2014)

Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature
por: Omura, Yoshiyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1t50j48m0jta5hd35r1kot784m